Join
Live feed
·
PRReleasevia Quantisnow
Takeda Pharmaceutical Company Limited logo

U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1

ByQuantisnow·Wall Street's wire, on your screen.
TAK· Takeda Pharmaceutical Company Limited
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track TAK (Takeda Pharmaceutical Company Limited) and more on Quantisnow.